- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Oral formulation of tenoxicam.
Relief of pain and inflammation in osteoarthritis
Relief of pain and inflammation in rheumatoid arthritis
Short term use in musculoskeletal disorders
20mg once daily taken at the same time.
Children under 18 years
History of peptic ulcer
Severe cardiac failure
Severe hepatic impairment
Severe renal impairment
Third trimester of pregnancy
Precautions and Warnings
Females attempting to conceive
Risk factors for cardiovascular disorder
Congestive cardiac failure
Connective tissue disorder
First trimester of pregnancy
Glucose-galactose malabsorption syndrome
History of asthma
History of cardiac failure
History of gastrointestinal disorder
Ischaemic heart disease
Peripheral arterial circulatory disorder
Second trimester of pregnancy
Systemic lupus erythematosus
May mask symptoms or signs of infections
May precipitate bronchospasm in patients with asthma or allergy
NSAIDs may provoke or exacerbate asthma
Consider the need for combination therapy with gastroprotective agents
Discontinue if signs of gastro-intestinal bleeding occur
Elderly: Monitor for gastrointestinal bleeding
If visual disturbances occur, perform ophthalmic evaluation
May affect platelet function
Monitor cardiac function in elderly patients
Monitor hepatic function in elderly patients
Monitor renal function in elderly patients
Discontinue if abnormal liver function tests persist or worsen
High dose/long term use may increase risk of arterial thrombotic events
May prolong bleeding time
Discontinue if symptoms of peptic ulcer occur
Discontinue treatment if skin rash or other allergic reaction occurs
Maintain treatment at the lowest effective dose
Maintain treatment for the shortest possible duration
May cause impaired fertility
Due to the high plasma protein-binding of tenoxicam, caution is required when plasma albumin concentrations are markedly reduced or when bilirubin concentrations are high.
In acute musculoskeletal disorders the length of the treatment should not exceed more than 7 days, but in severe cases it can be extended up to a maximum of 14 days.
In the presence of serious skin reactions tenoxicam should not be initiated or should be discontinued.
Combination therapy with protective agents (e.g. proton pump inhibitors or misoprostol) should be considered in patients with history of ulcer, particularly if complicated with hemorrhage or perforation, in the elderly and in patients requiring concomitant low dose of aspirin, or other drugs likely to increase gastrointestinal risk.
There may be an increased risk of aseptic meningitis in patients with systemic lupus erythematous and mixed connective tissue disorders.
In patients planned for major surgery, the increased bleeding time caused by the use of tenoxicam should be considered.
Pregnancy and Lactation
Tenoxicam is contraindicated during the third trimester of pregnancy but may be used with caution during the first and second trimester.
The use of tenoxicam in the third trimester is contraindicated by the manufacturer and the manufacturer advises, that tenoxicam should only be used in the first and second trimesters if clearly necessary.
In early pregnancy there may be an increased risk of foetal cardiovascular malformation. In late pregnancy there may be an increased risk of premature closure of the ductus arteriosus and renal dysfunction. At the end of pregnancy labour may be delayed due to inhibition of uterine contractions, and prolonged bleeding times may affect both mother and neonate.
Animal studies have shown some teratogenic effects of prostaglandin synthesis inhibitors during organogenetic period.
Tenoxicam is contraindicated during breastfeeding.
Manufacturer advises the discontinuation of tenoxicam or, if not possible, stopping breastfeeding.
Tenoxicam passes into breast milk after single dose administration.
Abnormal liver function tests
Congestive cardiac failure
Gastro-intestinal ulceration and bleeding
Increase in blood urea or creatinine
Increase in serum transaminases
Toxic epidermal necrolysis
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: November 2021
Summary of Product Characteristics: Mobiflex tablets 20mg. Meda Pharmaceuticals. Revised November 2020.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.